Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide +/- SBRT in Castration-Resistant Prostate Cancer (PILLAR)
NCT03503344Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by University of California, San Francisco. Started Dec 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03503344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503344.